SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2015

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

7. SUBSEQUENT EVENTS

On November 5, 2015, we announced that our partner Endo had exercised an early opt‑in for CCH to include two new potential indications, lateral thigh fat and plantar fibromatosis. We will receive a $0.5 million opt‑in fee for each indication. As a result of Endo’s early opt‑in for these two indications, Endo is now responsible for all costs for future clinical development. All other terms and conditions of the agreement remain the same, however, including Endo’s obligations with respect to developmental milestone payments and royalties and mark-up on cost of goods sold payments. We agreed to this early opt‑in which does not affect any of our other Stage I development activities including human lipomas and uterine fibroids. In addition to these two new indications, Endo’s current licensed rights also include Dupuytren’s contracture, Peyronie’s disease, adhesive capsulitis, cellulite and canine lipoma.